{"denoms":[{"counts":[{"groupId":"BG000","value":"278"},{"groupId":"BG001","value":"279"},{"groupId":"BG002","value":"277"},{"groupId":"BG003","value":"834"}],"units":"Participants"}],"groups":[{"description":"Participants received ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months).","id":"BG000","title":"Ipilimumab"},{"description":"Participants received pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months.","id":"BG001","title":"Pembrolizumab Q2W"},{"description":"Participants received pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months.","id":"BG002","title":"Pembrolizumab Q3W"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"14.2","value":"59.9"},{"groupId":"BG001","spread":"14.6","value":"59.9"},{"groupId":"BG002","spread":"13.6","value":"61.2"},{"groupId":"BG003","spread":"14.1","value":"60.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"116"},{"groupId":"BG001","value":"118"},{"groupId":"BG002","value":"103"},{"groupId":"BG003","value":"337"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"162"},{"groupId":"BG001","value":"161"},{"groupId":"BG002","value":"174"},{"groupId":"BG003","value":"497"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"The Intent-to-Treat (ITT) population consisted of all randomized participants. Participants were included in the group to which they were randomized for Baseline Characteristics."}